Skip to main content

Coda Minerals Seeks ASX Quotation for 1.56 Million New Shares

Tipranks - Fri Mar 6, 11:18PM CST

Claim 70% Off TipRanks Premium

An announcement from Coda Minerals Ltd ( (AU:COD) ) is now available.

Coda Minerals has applied for quotation on the ASX of 1,555,427 new ordinary fully paid shares, following the issue of these securities on 4 March 2026. The additional quoted shares, arising from the exercise or conversion of existing options or other convertible securities, will modestly increase the company’s free float and may enhance liquidity for existing and new shareholders.

The move underscores ongoing capital management and potentially reflects progress in incentive or financing structures tied to the company’s securities, though no operational or project-specific updates accompanied the filing. For investors, the disclosure primarily signals incremental equity dilution and a slightly expanded base of tradable Coda Minerals shares on the market.

The most recent analyst rating on (AU:COD) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Coda Minerals Ltd stock, see the AU:COD Stock Forecast page.

More about Coda Minerals Ltd

Coda Minerals Ltd is an Australian-listed resources company operating in the mining and minerals exploration sector. The company’s ordinary fully paid shares trade on the ASX under the ticker code COD, giving it access to equity capital markets for funding exploration and development activities.

Average Trading Volume: 929,866

Technical Sentiment Signal: Hold

Current Market Cap: A$70.68M

Learn more about COD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.